Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 10942501.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Polychemotherapy including idarubicin was administered during the second trimester to treat acute lymphoblastic leukemia. The infant delivered at 28 weeks' gestation had acute cardiac failure attributed to the cardiotoxic effect of idarubicin. Cardiotoxicity may be caused by idarubicin's biophysical properties that facilitate its transplacental passage. Idarubicin should be used with extreme caution during pregnancy.
Medical subject headings
- Adult
- Antibiotics, Antineoplastic
- Antibiotics, Antineoplastic/pharmacokinetics
- Antibiotics, Antineoplastic/poisoning
- Female
- Heart
- Heart/drug effects
- Humans
- Idarubicin
- Idarubicin/pharmacokinetics
- Idarubicin/poisoning
- Leukemia-Lymphoma, Adult T-Cell
- Leukemia-Lymphoma, Adult T-Cell/drug therapy
- Leukemia-Lymphoma, Adult T-Cell/metabolism
- Placenta
- Placenta/metabolism
- Pregnancy
- Pregnancy Trimester, Second